Meloxicam Stada

Meloxicam, the active ingredient in Meloxicam Stada, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for oral use. It is employed to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other acute musculoskeletal conditions.

GNH USA supplies Meloxicam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare providers through.

Meloxicam is an NSAID that reduces inflammation by inhibiting cyclooxygenase enzymes, and it is indicated for several musculoskeletal disorders. - Osteoarthritis: alleviates joint pain and swelling, helping improve function and quality of life. - Rheumatoid arthritis: decreases synovial inflammation and pain, supporting disease management alongside disease‑modifying agents. - Ankylosing spondylitis: reduces spinal stiffness and discomfort, facilitating greater mobility. - Acute pain: provides rapid relief of moderate to severe pain from injuries or postoperative settings.

Meloxicam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort (nausea, dyspepsia) - Headache - Dizziness - Peripheral edema - Elevated blood pressure

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Severe cardiovascular events (myocardial infarction, stroke) - Acute renal failure or worsening of chronic kidney disease - Life‑threatening skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)

Before prescribing meloxicam, clinicians should evaluate patient risk factors and monitor for potential complications. - Renal function: assess baseline kidney function and monitor periodically in patients with renal impairment. - Cardiovascular risk: use cautiously in individuals with history of heart disease, hypertension or stroke. - Gastrointestinal risk: avoid in patients with active peptic ulcer disease or a history of serious GI bleeding. - Pregnancy and lactation: consider potential fetal risks and discuss benefits versus hazards with pregnant or nursing women. - Drug interactions: review concomitant use of anticoagulants, other NSAIDs, or selective COX‑2 inhibitors. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Meloxicam can interact with several medicines, altering efficacy or safety; interactions are classified by clinical significance.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Concurrent NSAIDs or aspirin: additive gastrointestinal toxicity. - Selective COX‑2 inhibitors (e.g., celecoxib): heightened cardiovascular risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may exacerbate renal impairment and electrolyte imbalance. - Lithium: meloxicam can raise lithium serum concentrations, requiring level monitoring.